Pronova BioPharma ASA,(Public, OSL:PRON) formerly Pronova Biocare, is a Norway-based company engaged in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Its first commercialized product is branded as Omacor in most countries in Europe and Asia and as Lovaza in the United States. It is approved in the United States, as well as certain European and Asian markets as an adjunct to diet for the treatment of elevated levels of triglycerides.
The Company’s production facilities are located in Sandefjord, Norway, and Kalundborg, Denmark. The Company’s principal markets include the United States, Italy, Greece, Korea, France, Spain, the United Kingdom and Germany. Pronova BioPharma’s partners comprise Solvay (acquired by Abbot), Kuhnil, GlaxoSmithKline, Pierre Fabre, Ferrer, SPA and Takeda. It has one direct wholly owned subsidiary, Pronova BioPharma Norge AS, which in turn owns Pronova BioPharma Danmark A/S.